1. Home
  2. PPCB vs ARTL Comparison

PPCB vs ARTL Comparison

Compare PPCB & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.12

Market Cap

3.2M

Sector

N/A

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$8.12

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPCB
ARTL
Founded
2007
2011
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PPCB
ARTL
Price
$0.12
$8.12
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
1.2M
1.9M
Earning Date
02-17-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.85
52 Week High
$10.69
$28.60

Technical Indicators

Market Signals
Indicator
PPCB
ARTL
Relative Strength Index (RSI) 28.08 88.83
Support Level N/A $1.35
Resistance Level $0.40 $10.55
Average True Range (ATR) 0.02 0.75
MACD 0.00 0.63
Stochastic Oscillator 7.02 81.26

Price Performance

Historical Comparison
PPCB
ARTL

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: